UAB begins clinical trial of COVID drug given to Trump (al.com) {Univ. Alabama Birmingham}
Updated Oct 07, 11:13 AM; Posted Oct 07, 11:13 AM
By Dennis Pillion | dpillion@al.com
UAB Hospital is recruiting patients for clinical trials of new antibody treatments for COVID-19, including the Regeneron treatment administered to President Donald Trump last week.
The University of Alabama at Birmingham Hospital is helping to develop new techniques to combat the virus that has killed 210,000 Americans and 2,600 in Alabama. UAB is now testing the effectiveness of two new monoclonal antibody drugs and testing convalescent plasma, which is donated from people who have recovered from the virus.
“Our team is excited,” said Dr. Turner Overton, who is leading an outpatient trial for a monoclonal antibody treatment developed by Eli Lilly. “I’m really looking forward to being part of these studies to create a situation where we can have drugs to offer people in the outpatient setting and get our lives back to normal.”
***
How to sign up
People interested in volunteering for the trials at UAB are urged to call 205-934-6777, where an operator will gather some information and determine whether they might qualify for one of the trials.
Overton said the studies were recruiting patients who have COVID and are hospitalized, people who have tested positive but are not hospitalized and patients who do not have COVID-19 for vaccine trials. He said they are also interested in recruiting patients who have recovered from COVID-19 and may be able to donate plasma for those treatments.
“We’re recruiting across the spectrum of disease,” Overton said. “Really anybody and everybody who is interested in volunteering for a research study could call about participation.”
***
more: https://www.al.com/news/birmingham/2020/10/uab-begins-clinical-trial-of-covid-drug-given-to-trump.html
No mention in the article to any contribution by Eli Whitney. 
